Introduction
============

Brain abscesses (BAs) are severe sequelae of central nervous system infections, and their prevention and treatment remains a major challenge in the medical field ([@B8]). BAs are characterized as focally intracerebral lesions that are associated with the invasion of certain pathogens, the activation of resident parenchymal cells, and the influx and development of inflammatory cells into collections of pus surrounded by well-vascularized capsules ([@B27]). Intraparenchymal BA is a serious and potentially life-threatening condition and accounts for approximately 1 in 10,000 hospitalizations in the United States ([@B27]; [@B8]). The treatment of BAs necessitates multiple approaches, including medical and surgical therapies. Patients with BAs should receive prompt empiric antibiotic therapy, and the surgical drainage of purulent material is necessary in most cases of BA ([@B8]; [@B47]). The most effective antimicrobial therapy for BAs, however, can be defined only after the infecting pathogen has been isolated ([@B8]). The prevalence of antibiotic-resistant bacteria complicates the prevention and treatment of BAs. Thus, the development of alternative therapeutic strategies for BAs is urgently needed.

Although an etiological agent cannot be identified in some BA cases, the leading etiological agents of BA are streptococci and *Staphylococcus aureus* ([@B37]). A recent meta-analysis revealed that 34% (2,000/5,894) and 18% (1,076/5,894) of culture-positive BA cases could be attributed to infections with *Streptococcus* and *Staphylococcus* spp., respectively ([@B7]). *S. aureus* is a highly virulent and adaptable pathogen that is also a commensal species of human skin and nares ([@B54]). Approximately 25% of individuals are permanently colonized with *S. aureus* and are therefore at a high risk of staphylococcal infections ([@B35]; [@B14]; [@B28]). The emergence of methicillin-resistant *S. aureus* and vancomycin-intermediate *S. aureus* has aggravated the problem of bacterial drug resistance, which can result in the treatment failure of *S. aureus* infections with antibiotics ([@B23]). Antivirulence factor therapy has been proven as a powerful alternative intervention for *S. aureus* infections ([@B39]; [@B13]). *S. aureus* possesses numerous virulence factors, including adhesins, toxins, and factors for escaping from host immune defenses ([@B63]; [@B64]). The production of virulence factors by *S. aureus* may be strain-specific given the variability in the DNA sequences of *S. aureus* isolates ([@B3]). The wide range of outcomes related to *S. aureus* infections can be attributed to the ability of *S. aureus* to express different combinations of virulence factors in different infection sites ([@B63]). For example, coagulase and clumping factor A (ClfA) play specific roles in the pathogenesis of *S. aureus*-induced endocarditis ([@B43]). ClfA and ClfB act as key mediators in catheter-associated urinary tract infections caused by *S. aureus* ([@B59]). In a murine skin abscess model, the virulence of *S. aureus* strain Newman was impaired upon the deletion of the immune evasion molecule staphylococcal protein A gene (*spa*), the fibronectin-binding protein genes *fnbAB* and *clfA*, or the surface protein gene *sasF*; these genes, however, do not participate in the development of dermonecrosis ([@B31]). Renal abscess formation caused by *S. aureus* Newman involves the heme-scavenging factors IsdA and IsdB; the adhesins SdrD, Emp, and Eap; and the immune evasion factor SpA ([@B14]).

In BA pathogenesis, *S. aureus* may originate continuously from a local source, such as the ears and nose, or from a hematogenously disseminated systemic infection ([@B47]). Thus far, however, the virulence determinants involved in BA with *S. aureus* origins remain unclear. In this study, we used a murine model of ear colonization (EC) to represent the ecological niche of *S. aureus* and a murine model of bacteremia (BM) to mimic the hematogenous dissemination of *S. aureus* in BA. We compared the expression levels of 42 putative virulence determinants of *S. aureus* strains Newman and XQ in the mouse models of BA, EC, and BM through reverse transcription-quantitative real-time polymerase chain reaction (RT-qPCR) analysis. We confirmed alterations in gene expression levels through specific TaqMan RT-qPCR. We validated the functions of persistently upregulated *S. aureus* virulence genes in BA formation through isogenic mutant experiments. We found that the therapeutic application of monoclonal antibodies (mAbs) against Hla and SpA inhibited BA formation in mice infected with the wild-type *S. aureus* Newman strain. Our data provide novel insights into the virulence determinants that contribute to staphylococcal BA formation and will help guide the development of an antivirulence paradigm for the treatment of *S. aureus*-induced BA.

Materials and Methods {#s1}
=====================

Bacterial Strains and Cultures
------------------------------

All bacterial strains and plasmids used in this study were listed in [Supplementary Table S1](#SM1){ref-type="supplementary-material"}. *S. aureus* Newman (NCTC 8178, ST1/*agr* I) was isolated from a throat swab from a patient suffered from secondarily infected tubercular osteomyelitis ([@B17]; [@B42]). *S. aureus* XQ (ST121/*agr* IV) is a highly virulent strain isolated from a 16-year-old juvenile, whose onset was a skin wound then deteriorated to a lethal *S. aureus* sepsis with mental disorder ([@B48]; [@B33]). *S. aureus* strains were cultured on tryptic soy agar (Oxford, the United Kingdom) or in tryptic soy broth (TSB, Oxford) at 37°C with shaking at 200 rpm overnight, then diluted 1:100 in TSB for culture or harvested in mid-log phase by centrifugation for inoculation. After washed twice by sterile PBS, the pellets were resuspended in PBS for use. *Escherichia coli* strain DH5α was cultivated in Luria Broth (LB) medium (Oxoid) supplemented with proper antibiotics for maintaining certain plasmids.

Construction of Murine Models Through *S. aureus* Infection
-----------------------------------------------------------

BALB/c-nu/nu mice (female, 6 weeks old) and C57BL/6 mice (6--8 weeks of age) were purchased from the Experimental Animal Centre of the Army Medical University (AMU). This study was carried out in accordance with the recommendations of the Regulations for the Administration of Affairs Concerning Experimental Animals approved by the State Council of People's Republic of China. The protocol was approved by the local ethics board at the Laboratory Animal Welfare and Ethics Committee of Army Medical University (\#SYXK-PLA-20120031).

For BA model, female C57BL/6 mice (*n* = 10) were anesthetized with 1% pentobarbital sodium (50 mg/kg, Sigma--Aldrich, the United States). A middle longitudinal incision was made along the scalp from ear to eye, exposing the frontal sutures. The mouse head was fixed in a stereotactic frame and drilled a hole near the bregma (1 mm rostral, 2 mm lateral to the right of bregma). A suspension of 5 μl prepared *S. aureus*-encapsulated agarose beads (1 × 10^5^ CFU) was injected 3 mm deep into the brain by microsyringe through the hole, waiting for 2 min after the infusion to minimize efflux. The pure agarose beads were injected and served as blank control. Pull out the needle slowly, and suture the skin as described ([@B4]; [@B6]). Three days after infection, mice were euthanized. The brain tissues were immersed in RNAlater (Qiagen, Germany), incubated at 4°C overnight for RNA extraction.

For EC model, both ears of BALB/c-nu/nu mice (*n* = 10) were colonized with 1 × 10^8^ CFU of *S. aureus* strain Newman or XQ. Mice were kept in individually ventilated cages to prevent contamination. Seventy-two hours later, the external acoustic meatus of each mouse were wiped by wet swabs with 100 μl RNAlater (Qiagen) for sample collection, and then the samples were stored at 4°C overnight before RNA extraction.

For BM model, C57BL/6 mice (*n* = 10) were injected with 1 × 10^8^ CFU of *S. aureus* strain Newman or XQ in 100 μl PBS through tail vein injection. One hour after injection, mouse blood was collected by heart punctuation after anesthetized with 1% pentobarbital sodium, and immediately mixed with 10 volumes of cold EL buffer (Qiagen). The mixture was then incubated on ice for 10 min with intermittent vortex mixing to split the erythrocytes thoroughly. The mixture of leukocytes and bacteria was harvested by centrifuging at 4,500 × *g* for 10 min at 4°C. The pellets were resuspended in an equal blood volume of ice-cold RNase-free water, pooled into two volumes of RNAprotect Bacteria Reagent (Qiagen). Finally, *S. aureus* cells were gathered by centrifugation and resuspended in TriPure (Roche Life Science, Switzerland).

Three independent experiments with 10 mice each were performed as biological repetitions.

Total RNA Extraction
--------------------

The ear swabs and centrifuged pellets were resuspended in 1.2 ml of pre-chilled buffer RLT from RNeasy Mini Kit (Qiagen) supplemented with 1% β-mercaptoethanol (Sigma--Aldrich). The mixture was transferred to lysing matrix B tubes (MP Biomedicals, the United States), then followed by mechanical disruption in a Mini Bead Beater (Biospec, the United States) for three cycles with 40 s each and 2 min interval incubation on ice. After centrifugation at 13,500 × *g* for 5 min, the supernatant was transferred to the RNeasy Mini Kit column for the following procedures of RNA extraction according to the manufacturer's instructions. DNase (Qiagen) treatment was performed with optional on-column DNA digestion. Finally, RNA was eluted with RNase-free water as described ([@B12]).

The RNA extraction procedures of BM and BA samples followed the standard phenol/chloroform/isopropanol protocol with some modifications. The specimen was disrupted by bead-milling submerged in TriPure as the aforementioned mechanical disruption process ([@B25]). The RNA pellet was resuspended in RNase-free water, digested with RNase-free DNase (Promega, the United States) for 1 h. Afterward, the TriPure extraction and DNase digestion procedures were repeated once to eliminate residual DNA. Finally, clean up of RNA was performed by using the RNeasy Mini Kit, and the eluting RNA was diluted in RNase-free water for reverse transcription.

RT-qPCR
-------

Reverse transcription was performed by SuperScript III cDNA Synthesis Kit (Invitrogen Corporation, the United States) following the manufacturer's recommendations. The 16S rRNA gene was used as the reference gene according to the observation of its expression variation never exceeded twofold in different growth conditions ([Supplementary Figure S1](#SM1){ref-type="supplementary-material"}). SYBR^®^Green qPCR was performed using SsoAdvanced Universal SYBR^®^Green Supeimix (Bio-Rad, the United States) with the cDNA as templates in the 7500 Real-Time PCR System (Applied Biosystems, the United States). For TaqMan qPCR, probes for the candidate genes were designed and were 5′-FAM (reporter) and 3′-TAMRA (quencher) labeled ([Supplementary Table S2](#SM1){ref-type="supplementary-material"}). TaqMan qPCR was carried out using Platinum Taq DNA Polymerase mix (Thermo Fisher Scientific, the United States) with standard cycling protocols, and data were analyzed using StepOne Software (Applied Biosystems, the United States). All primer pairs (listed in [Supplementary Table S2](#SM1){ref-type="supplementary-material"}) were identical for SYBR^®^Green and TaqMan-based qPCR to ensure consistency as much as possible for the same gene between the two methods.

Construction of In-frame Gene Deletions
---------------------------------------

To construct isogenic markerless knockout mutants of *S. aureus* Newman, the in-frame gene deletions were performed by allelic replacement using the temperature-sensitive *E. coli* and *S. aureus* shuttle vector pBT2 as previously described ([Supplementary Figure S2A](#SM1){ref-type="supplementary-material"}; [@B62]). Each mutant of interest was verified by PCR amplification with certain primers listed in [Supplementary Table S2](#SM1){ref-type="supplementary-material"} and DNA sequencing.

Bacterial Load Counting in Mouse Brain
--------------------------------------

Five days after intracranial inoculation with *S. aureus* Newman or mutant strains, mice were implemented euthanasia. The whole brain was taken and homogenized with 1 ml of 1% Triton X-100 (Sigma-Aldrich) in PBS, then serially diluted (10-fold) for the enumeration of viable bacteria by plating on tryptic soy agar and cultured for 24 h at 37°C.

Histological Examination and Brain Abscess Volume Computation
-------------------------------------------------------------

Five days after infection, mice were euthanized and the brain was removed and fixed in 4% paraformaldehyde. The infiltrated brain tissues were then embedded in paraffin. Serial sections in 4 μm thickness were sampled every 100 μm throughout the brain and stained with hematoxylin and eosin (H&E). Each section was examined and photographed under bright field microscopy (BX52, Olympus, Japan) at 2× or 40× objective magnification. The BA volumes were computed by Image J (NIH, the United States) as described ([@B6]).

mAb Therapy for Murine Brain Abscess
------------------------------------

Anti-Hla and anti-SpA mAbs of murine origin (BALB/c) were kindly provided by Prof. Hao Zeng (AMU). In the treatment group, a combination of modified anti-Hla mAbs (including two clones of 4D11 and 7G4) and anti-SpA mAbs (including 2H4 and 8C3 clones) diluted in 100 μl PBS was injected intraperitoneally (i.p.) into C57BL/6 mice (5 mg/kg). For the control group, the same volume of PBS was given instead. BA models were established 24 h after i.p. administration. Five days later, the two groups of BA mice were euthanized for bacterial load counting and BA volume calculation as aforementioned.

Three-Dimensional Reconstruction of Brain Abscess
-------------------------------------------------

Histological sections of mouse brain infected with *S. aureus* Newman pretreated with or without mAbs against Hla and SpA were prepared by sampling every 100 μm and photographed in sequence by microscopy at 20× magnification. The visible brain structures including the abscess in each section were circled using the histological sections slide by slide with Amira software (version 5.2.2) and the three-dimensional (3-D) structure of the infected murine brain was reconstructed by Cinema 4D R18 ([@B49]).

Statistical Analysis
--------------------

Statistical analysis of results was carried out using GraphPad Prism 7. Unpaired two-tailed Student's *t*-test was used to treat samples between two groups, and Mann--Whitney test was used for testing multiple groups. Each experiment was carried out at least thrice. Results are presented as mean ± standard deviations (SD), and a *P*-value \<0.05 was considered statistically significant. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001, and ns represented no significance.

Results
=======

Establishment of Mouse BA Models and RT-qPCR Analysis of the Expression Levels of *S. aureus* Virulence Genes
-------------------------------------------------------------------------------------------------------------

We used the *S. aureus* Newman and XQ strains to establish mouse models of BA. *S. aureus* Newman (ST1/*agr* I) has been widely used to construct animal models of staphylococcal diseases because of its stable *agr* phenotype ([@B43]; [@B14]; [@B42]; [@B63]; [@B31]; [@B64]). *S. aureus* XQ (ST121/*agr* IV) is a highly virulent clinical strain collected by our laboratory ([@B48]). The complete genome sequences of the Newman and XQ strains have been uploaded to GenBank with accession numbers of [AP009351.1](AP009351.1) and [CP013137.1](CP013137.1), respectively ([@B3]; [@B33]). These strains express strain-specific virulence factors but also share numerous common virulence determinants ([Supplementary Figure S3](#SM1){ref-type="supplementary-material"}). The clinical course developed by C57BL/6 mice after intracranial injection with *S. aureus*-encapsulated agarose beads was similar to that developed by previously reported BA models ([@B4]; [@B6]). Gross specimens revealed the formation of focal BAs in the parenchymal area of the murine brain ([Figure 1A](#F1){ref-type="fig"}). Histochemical staining (H&E) and examination of infected brains at days 5 post infection revealed well-circumscribed abscesses with neutrophil and macrophage infiltration and drastic mass effects and midline shifts ([Figure 1B](#F1){ref-type="fig"}). The pure agarose beads without *S. aureus* (blank control) injected mice were unable to form BA, only a needle passway remained ([Supplementary Figure S4](#SM1){ref-type="supplementary-material"}).

![Comparison of the expression levels of virulence genes under *in vivo* and *in vitro* conditions. **(A)** Mouse BA model induced by *S. aureus*. Gross view of an abscess prominent in the brain collected from a model mouse at 5 days after infection with the Newman strain (black arrowhead). **(B)** Hematoxylin and eosin (H&E) staining and examination of brain section collected from a model mouse at 5 days post infection revealed a well-circumscribed abscess at low magnification (20×, left panel) and a defined abscess with neutrophil and macrophage infiltration and abscess capsule margin (yellow arrowheads) in the normal brain tissue (black arrowheads) at high magnification (400×, right panel). **(C)** A heatmap showed fold changes in the expression levels of virulence genes in BA, TSB, and RPMI. Results are presented as mean fold of upregulation (shades of red) and downregulation (shades of blue) in three separate samples after detection by SYBR^®^Green RT-qPCR (see scale bar). Fourty-two virulence genes were divided into three groups (adhesins, toxins, and immune evasion factors) and their functions were indicated after Gene Ontology analysis.](fmicb-10-00682-g001){#F1}

Bacterial gene expression profiles under *in vitro* conditions differ from those under *in vivo* conditions ([@B25]). We applied SYBR^®^Green RT-qPCR to determine variations in *S. aureus* gene expression in response to environmental changes. We used TSB and RPMI medium 1640 (RPMI), the typical media used for culturing bacteria and eukaryotic cells, respectively, to represent *in vitro* conditions and establish baseline conditions ([@B25]). We utilized the mouse BA model to represent the *in vivo* environment. The 16S rRNA gene served as an internal control for the normalization of gene expression level because its expression in Newman and XQ strains under various *in vitro* growth conditions varied by less than twofold ([Supplementary Figure S1](#SM1){ref-type="supplementary-material"}). We performed a control PCR assay based on the *Pseudomonas aeruginosa pcrV* gene in a plasmid to exclude possible copurified contaminants. We amplified the *pcrV* gene with similar efficiency from all samples. This result suggests that none of the purified cDNA samples affected PCR efficiency ([Supplementary Figure S5](#SM1){ref-type="supplementary-material"}). The expression levels of 42 putative virulence determinants of Newman and XQ strains ([Supplementary Table S3](#SM1){ref-type="supplementary-material"}) were determined and normalized to those of the 16S rRNA gene. We categorized the 42 virulence determinants as adhesins, toxins, or immune evasion factors ([@B63]; [@B5]). The fold changes in the expression levels of each virulence gene in BA versus those in TSB or RPMI (baseline) were calculated and shown as a heatmap ([Figure 1C](#F1){ref-type="fig"}). In at least one strain, the expression levels of most adhesin genes were upregulated from 2.2-fold to 32,000-fold during the transition from external growth to internal BA formation. In both strains, the transcription levels of the adhesion genes *clfA, emp, hrtA, sasF*, and *sdrC* increased under *in vivo* conditions relative to those under *in vitro* culture conditions. In both strains, the expression levels of *isdA, isdB, isdC, isdH*, and *mntC*, which are all adhesins related to metal cation transport, were upregulated under *in vivo* conditions relative to those under *in vitro* culture conditions. These results, however, did not hold true for XQ in RPMI. During BA formation, the expression levels of the typical pore-forming toxin genes *hla, hlgB, lukF-PV* (*pvlF*), and *ssl5* consistently increased, whereas those of genes encoding immune evasion factors varied ([Figure 1C](#F1){ref-type="fig"}).

Differential Expression Patterns of Virulence Determinants in Murine Models of BA, EC, and BM
---------------------------------------------------------------------------------------------

Skin-colonizing and hematogenously disseminated *S. aureus* are major sources of brain infections after traumatic brain injuries and neurosurgical procedures ([@B4]; [@B6]; [@B47]). We used BALB/c-nu/nu mice instead of C57BL/6 mice to establish the EC model because bacteria were eliminated from the external auditory skin of C57BL/6 mice within 1 week after inoculation with *S. aureus* ([@B26]). We successfully developed the mouse model of *S. aureus*-induced BM by intravenously injecting *S. aureus* Newman or XQ into C57BL/6 mice. We used the EC model to represent skin colonization with commensal *S. aureus* under normal physical conditions and the BM model to represent systemic infection. We hypothesized that the virulence profiles of *S. aureus* in the BA model differ from those in the EC and BM models. The schematic of the experiment that we performed to identify the potential virulence determinants involved in BA formation is shown in [Figure 2A](#F2){ref-type="fig"}. SYBR^®^Green RT-qPCR was applied to investigate the changes in the expression levels of the 42 putative virulence genes ([Supplementary Table S3](#SM1){ref-type="supplementary-material"}) in the EC and BM models. As indicated in [Figure 2B](#F2){ref-type="fig"}--[D](#F2){ref-type="fig"}, the expression levels of all 42 selected genes of the Newman and XQ strains, except for those of *clfA* and *essA* of the Newman strain and *icaD* of the XQ strain, increased by more than twofold in the BA model relative to those in the EC model. Among these genes, the expression levels of 11 adhesion genes (*clfA, clfB, emp, fnbA, hrtA, isdA, isdB, isdC, mntC, sasF*, and *icaA*), 6 toxin genes (*pvlF, adsA, aur, lgt, sak*, and *vwb*), and 3 immune evasion factor genes (*essA, efb*, and *sbi*) of at least one strain were significantly upregulated (*P* \< 0.05). Similarly, the expression levels of all selected genes of the Newman and XQ strains, except for those of *sasF* of the XQ strain, increased by more than twofold in the BM model relative to those in the EC model ([Supplementary Figure S6](#SM1){ref-type="supplementary-material"}). These results indicate that the brain and blood represent more challenging infectious status than skin colonization for *S. aureus*. The expression levels of 78.6% (33/42) of the detected genes of the Newman and XQ strains decreased by more than twofold in the BA model relative to those in the BM model ([Figure 3](#F3){ref-type="fig"}). The expression levels of the adhesin genes *emp* and *tarK*, toxin gene *adsA*, and immune evasion gene *ecb* of both strains were significantly downregulated in the BA model relative to those in the BM model (*P* \< 0.05). The expression levels of *isdA, isdB, isdC, sasF, sdrC, hla, pvlF, aur*, and *spa* of at least one strain were upregulated in the BA model relative to those in the BM model. These genes have crucial roles in the development of BAs through *S. aureus* infection ([Figure 3](#F3){ref-type="fig"}).

![RT-qPCR detection of the expression levels of virulence determinants in the murine models of BA and EC. **(A)** Schematic of the experiment performed to identify key virulence determinants that contribute to the formation of BA induced by *S. aureus*. BALB/c-nu/nu or C57BL/6 mice were infected with the indicated dose of *S. aureus* Newman or XQ. Samples were then collected at 1 or 72 h after bacterial infection and subjected to SYBR^®^Green RT-qPCR for the detection of 42 virulence genes. The 23 genes of interest were further confirmed through TaqMan RT-qPCR analysis. The expression patterns of *S. aureus* genes in the BA model were compared with those in the EC and BM models. The functions of screened genes were further identified through isogenic mutant experiments. SYBR^®^Green RT-qPCR detection of virulence profiles. **(B)** Adhesin genes, **(C)** Toxin genes, and **(D)** Immune evasion factor genes in the mouse models of BA and EC. The transcript levels of genes were normalized to those of the 16S rRNA gene, and results for the BA model were compared with those for the EC model. The *S. aureus* strains Newman (green bars) and XQ (orange bars) were analyzed. Results are from three independent experiments with 10 animals/experiment. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001 (Student's *t*-test).](fmicb-10-00682-g002){#F2}

![Variations in the expression patterns of virulence determinants in murine models of BA and BM. The transcript levels of genes were normalized to those of the 16S rRNA gene, and results for the BA model were compared with those for the BM model. The *S. aureus* strains Newman (green bars) and XQ (orange bars) were analyzed. Results are from three independent experiments with 10 animals/experiment. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001. **(A)** Adhesin genes, **(B)** toxin genes, and **(C)** immune evasion factor genes.](fmicb-10-00682-g003){#F3}

TaqMan RT-qPCR and Isogenic Mutant Analyses of Virulence Determinants That Contribute to BA Formation by *S. aureus*
--------------------------------------------------------------------------------------------------------------------

The TaqMan approach exhibits high reproducibility, specificity, and sensitivity, as well as low sensitivity to genomic DNA contaminants in RNA samples ([@B2]). We applied the TaqMan RT-qPCR approach to confirm the expression patterns of the genes that were identified through SYBR^®^Green RT-qPCR. We selected nine genes (*isdA, isdB, isdC, sasF, sdrC, hla, pvlF, aur*, and *spa*) that were upregulated in the BA model relative to those in the BM model ([Figure 3](#F3){ref-type="fig"}). We also selected 14 genes (*clfA, clfB, emp, fnbA, hrtA, mntC, icaA, adsA, lgt, saK, vwb, essA, efb*, and *sbi*) with expression levels that were significantly upregulated in at least one strain in the BA model relative to those in the EC model ([Figure 2](#F2){ref-type="fig"}, *P* \< 0.05) but were downregulated in the BA model relative to those in the BM model. We found that the expression levels of all tested virulence genes, except for those of *hrtA* and *icaC* of the XQ strain, increased by at least twofold ([Figure 4A](#F4){ref-type="fig"} and [Supplementary Figure S7](#SM1){ref-type="supplementary-material"}). Among the detected genes, the expression levels of *isdB, sasF, hla, pvlF*, and *spa* of both strains were significantly upregulated in the BA model relative to those in the EC model (*P* \< 0.05). The expression levels of other 18 genes, except for *adsA*, of at least one strain were markedly upregulated in the BA model relative to those in the EC model ([Figure 4A](#F4){ref-type="fig"}). Notably, the expression levels of 13 selected genes (56.5%, 13/23) were upregulated. Six genes of at least one strain were significantly enriched (*isdA, isdB, isdC, sasF, sdrC*, and *adsA*) in the BA model relative to that in the BM model ([Figure 4B](#F4){ref-type="fig"}, *P* \< 0.05). These results are similar to those detected through SYBR^®^Green RT-qPCR ([Figure 3](#F3){ref-type="fig"}).

![Confirmation of virulence gene expression through TaqMan RT-qPCR. The TaqMan probes designed for the virulence genes were listed in [Supplementary Table S2](#SM1){ref-type="supplementary-material"}. The transcript levels of genes were normalized to those of the 16S rRNA gene, and results for the BA model were compared with those for the EC **(A)** and BM **(B)** models. The *S. aureus* strains Newman (green bars) and XQ (orange bars) were analyzed. Results are from three independent experiments with 10 animals/experiment. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001.](fmicb-10-00682-g004){#F4}

To confirm that the above virulence determinants are required in BA formation by *S. aureus*, we attempted to construct isogenic mutants by using five genes (*isdB, sasF, hla, pvlF*, and *spa*) of both strains with expression levels that were significantly upregulated in the BA model relative to those in the EC model ([Figure 4A](#F4){ref-type="fig"}, *P* \< 0.05), three consistently upregulated genes (*isdA, isdC*, and *aur*) of both strains with expression levels that were upregulated in the BA model relative to those in the BM model, and two genes (*sdrC* and *adsA*) of the Newman strain with expression levels that were upregulated in the BA relative to those in the BM model ([Figure 4B](#F4){ref-type="fig"}). We also selected the *lgt* gene. The expression level of the *lgt* gene of XQ was significantly upregulated in the BA model relative to that in the EC model (*P* \< 0.001), whereas that of the *lgt* gene of both strains was slightly downregulated in the BA model relative to that in the BM model ([Figure 4](#F4){ref-type="fig"}). Given that *S. aureus* XQ is a clinical isolate and is difficult to genetically manipulate ([@B33]), we constructed isogenic mutants with a Newman background. Eight single-gene mutants were successfully constructed through homologous DNA recombination without any selection markers ([Supplementary Figure S2A](#SM1){ref-type="supplementary-material"}) and verified through PCR amplification and DNA sequencing ([Supplementary Figures S2B--I](#SM1){ref-type="supplementary-material"}). The unsuccessful deletion of *isdB, pvlF*, and *adsA* may attribute to problems with the applied technique ([@B62]). We also constructed three double-gene mutants (Δ*hla*/Δ*spa*, Δ*sdrC*/Δ*aur*, and Δ*sdrC*/Δ*sasF*) to evaluate the synergism between the selected genes. BA models were separately established with the wild-type Newman and mutant strains. The brain bacterial loads of mice infected with the mutant strains were quantified and compared with those of mice infected with the wild-type Newman strain. The colony-forming units (CFUs) of the *isdA, isdC, lgt, hla*, or *spa* deletion mutants and those of the *hla*/*spa* double mutant were lower than those of the wild-type Newman strain, whereas those of the *sdrC, aur, sasF, sdrC*/*aur*, or *sdrC*/*sasF* knockout mutants did not differ from those of the wild-type Newman strain ([Figure 5A](#F5){ref-type="fig"}).

![Isogenic mutant analysis of virulence determinants that contribute to BA formation through *S. aureus* infection. **(A)** CFU enumeration of wild-type Newman and mutant strains in the BA model. Groups of 10 mice each were challenged intracranially with 5 μl of agarose beads encapsulated with 1 × 10^5^ CFU of *S. aureus*. At 5 days after infection, the number of the viable organisms associated with BA was determined by quantitative culture. Titers are expressed as the mean log (CFU) per mouse in the brain homogenate. **(B)** H&E-stained brain sections collected from mice at 5 days post infection with wild-type Newman or mutant strains. For each strain, sections collected from a representative mouse brain revealed a focal intracerebral lesion (20×, top panel) and a well-defined abscess surrounded by a clear boundary (yellow arrows) within the normal brain tissue (black arrows, 400×, bottom panel). **(C)** BA volume calculation of mice infected with the wild-type Newman or mutant strains. The abscess areas of each brain section slide were evaluated.](fmicb-10-00682-g005){#F5}

Hematoxylin and eosin-stained brain sections collected from mice at 5 days after infection with the wild-type Newman or mutant strains exhibited typical BA formations that were characterized by focal intracerebral lesions with clear boundaries ([Figure 5B](#F5){ref-type="fig"}). We calculated the BA volume through ImageJ software as previously described ([@B6]). In accordance with the bacterial load results, the volumes of BAs resulting from infection by the *isdA, isdC, lgt, hla*, or *spa* deletion mutants and those from infection by the *hla*/*spa* double mutant significantly decreased relative to those of BAs resulting from infection by the wild-type Newman strain (*P* \< 0.05), whereas of BAs resulting from infection with *sasF, sdrC, aur, sdrC*/*sasF*, or *sdrC/aur* mutants and wild-type strain negligibly differed ([Figure 5C](#F5){ref-type="fig"}). Taken together, these data indicate that the *isdA, isdC, lgt, hla*, and *spa* genes are required for BA formation through *S. aureus* infection. Potential antivirulence strategies that target these specific determinants may be developed for the treatment of *S. aureus*-induced BA infections.

Mitigation of Staphylococcal BA Formation in Mice by Antivirulence Treatment
----------------------------------------------------------------------------

We tested the anti-BA activities of mAbs against certain virulence determinants to determine the potential of their potential as antivirulence targets in the treatment of BA caused by *S. aureus* infection. Different mAbs that target different epitopes may exert synergistic protective effects when coadministered ([@B15]). We administered mAbs against Hla and SpA to C57BL/6 mice through intraperitoneal injections. On the day after mAb treatment, we cerebrally infected mice with the wild-type Newman strain to establish BA infections. Bacterial load and BA volume were quantified at 5 days postinfection. As shown in [Figure 6A](#F6){ref-type="fig"}, the viable bacterial counts in the murine BA model treated with mAbs against Hla and SpA significantly decreased relative to those in the model treated with PBS (*P* \< 0.05). Although histological examinations revealed that BA lesions with similar characteristics developed under treatment with PBS and mAbs ([Figure 6B](#F6){ref-type="fig"}), BA volumes significantly decreased under treatment with mAbs ([Figure 6C](#F6){ref-type="fig"}, *P* \< 0.01). This result was also confirmed through 3-D modeling ([Figure 6D](#F6){ref-type="fig"}). Overall, these results show that treatment with specific antibodies against virulence determinants may reduce the pathogenicity of *S. aureus*-induced BA and thus represents an alternative strategy for the clinical treatment of brain infections caused by *S. aureus*.

![Synergistic anti-BA activities of mAbs against *S. aureus* Hla and SpA. **(A)** Bacterial loads. A group of 10 mice were each pretreated i.p. with mAbs against Hla and SpA (10 μg/kg) and then challenged intracranially with agarose beads encapsulated with 1 × 10^5^ CFU of *S. aureus* wild-type Newman strain. The PBS-treated mice served as negative control. Five days after infection, the number of viable organisms associated with BA was determined by quantitative culture. Titers are expressed as the mean log (CFU) per mouse of brain homogenate, ^∗^*P* \< 0.05. **(B)** Histological examination showed BA lesions with similar characteristics developed under treatment with PBS and mAbs. **(C)** BA volumes. BA volume of each mouse was calculated based on the 3-D structure of BA constructed by using BA histological section slides. *n* = 6, **^∗∗^***P* \< 0.01. **(D)** Three-dimensional reconstruction of the representative mouse brain showed the location and volume of BA after PBS or mAbs treatment. See 3-D animation in [Supplementary Figures S8](#SM1){ref-type="supplementary-material"}, [S9](#SM1){ref-type="supplementary-material"}.](fmicb-10-00682-g006){#F6}

Discussion
==========

*Staphylococcus aureus* can colonize and infect various sites of the human body because of its ability to employ different sets of virulence factors during adaptation to specific niches ([@B63]). Adhesin genes, such as *clfB, sdrC, sdrD, sasG*, and *tarK*, have important roles in the commensal lifestyle of *S. aureus* ([@B9],[@B10]). The genes *clfA, tagO*, and *fnbA* have been implicated in the development of *in vivo* organ infection ([@B60]; [@B14]; [@B39]). The complexity of the *in vivo* setting hinders the exploration of bacterial gene expression in the host environment ([@B25]). Many studies have applied *in vitro* systems to mimic *in vivo* environments, including environments defined by low oxygen and nutrient levels ([@B34]; [@B51]; [@B36]). Different virulence determinants are required in the infection of different body sites by *S. aureus*. The factors required in the formation of BA through *S. aureus* infection, however, have not been elucidated to date. In this study, we specifically aimed to characterize the roles of 42 putative virulence determinants in BA formation through *S. aureus* infection and screen potential therapeutic targets. We analyzed and compared the virulence gene expression of two *S. aureus* strains in mouse models of BA, EC, and BM. We selected the EC and BM models to represent the stepwise development of BA through infection by skin-colonizing *S. aureus* after brain injury or by hematogenously disseminated *S. aureus*.

The *in vivo* environment imposes immune stress and metal cation limitations on bacterial pathogens ([@B25]). Our RT-qPCR results revealed that the expression levels of all virulence genes, except for those of the *clfA* and *essA* genes of the Newman strain and the *icaD* gene of the XQ strain, increased during the transition from EC to BA ([Figure 2](#F2){ref-type="fig"}). The variations in the expression patterns of these genes coincide with the transformation of *S. aureus* from a commensal species to a pathogenic species and reflect the strategies used by *S. aureus* to counteract the host immune system and facilitate metal cation acquisition. During the transition from BM to BA, the expression levels of 78.6% of the selected virulence genes were downregulated. The *isdA, isdB, isdC, sasF, sdrC, hla, pvlF, aur*, and *spa* ([Figure 3](#F3){ref-type="fig"}) genes of at least one strain were upregulated during BM to BA transition and likely play important roles in BA formation through *S. aureus* infection. Thus, we subjected these 9 genes and other 14 genes with expression levels that were significantly upregulated during EC to BA transition ([Figure 2](#F2){ref-type="fig"}) to TaqMan qPCR analysis and isogenic mutant experiments. We demonstrated for the first time that the five enriched genes *isdA, isdC, lgt, hla*, and *spa* are required in BA formation through *S. aureus* infection.

Bacterial adherence is the first and one of the most important steps in host tissue colonization and disease development ([@B43]; [@B39]; [@B31]; [@B59]). ClfA and ClfB adhesins are required during the early stage of renal abscess formation by *S. aureus* ([@B14]). We characterized the expression patterns of typical *S. aureus* adhesin genes, including *aaa, fnbA, fnbB, sasF, sdrC*, and the extracellular adhesin genes *clfA, clfB, emp*, and *eap* ([@B14]; [@B63]), in mouse models of BA, EC, and BM and found that none of these genes were enriched during BA formation ([Figure 2A](#F2){ref-type="fig"}). This result may be attributed to our use of *S. aureus*-encapsulated agarose beads to establish the BA model ([@B4]; [@B6]). Agarose may have protected *S. aureus* cells from environmental pressures during the early colonization stage. Notably, the Newman strain lacks functional FnbAB proteins ([@B45]). The putative virulence determinant SdrC can bind the neuronal cell-adhesion molecule β-neurexin to stabilize adhesion and plays a central role in the colonization of the nasal cavity by *S. aureus* ([@B53]). Nevertheless, the deletion of *sdrC* did not impair bacterial virulence in the mouse model of BA. SasF is an important component in biofilm matrix formation by *S. aureus* during acute bone implant infection ([@B32]). It participates in skin abscess formation in mice but not in renal abscess pathogenesis ([@B14]; [@B31]). The decrease in the brain CFUs of the Δ*sasF* mutant and the Δ*sasF*/Δ*sdrC* mutant suggests that SasF does not participate in *S. aureus*-induced BA. Notably, the results of TaqMan qPCR detection revealed that the expression levels of the *isd* genes of adhesins, which are responsible for scavenging iron from hemoproteins and transporting heme iron into *S. aureus* ([@B63]), of at least one strain were upregulated in the BA model relative to those in the BM model. In the murine BA model, the virulence of Newman mutants with *isdA* or *isdC* deletions was attenuated compared with that of wild-type strain. The *mntC* gene, which is associated with manganese transport, showed limited importance in BA formation by *S. aureus* ([Figure 4](#F4){ref-type="fig"}). Iron content varies among different organs and tissues, and *S. aureus* responds to iron restriction in host niches through the coordinated upregulation of iron acquisition pathways ([@B21]). Our data further support that cell wall-anchored Isd proteins play important roles in the development of BA through *S. aureus* infection ([@B38]; [@B21]). We attempted to identify the potential role of the *lgt* gene in BA formation. The *lgt* gene is a member of the toxin group and encodes diacylglyceryl transferase, which contributes to the maturation of lipoproteins ([@B46]). Our TaqMan qPCR detection results showed that the expression levels of the *lgt* genes of both strains were upregulated in the BA model relative to those in the EC model and were slightly downregulated in the BA model relative to those in the BM model ([Figure 4](#F4){ref-type="fig"}). The bacterial loads of the *lgt* deletion mutant significantly decreased in the mouse brain (*P* \< 0.05). The BA volume of mice infected with the *lgt* deletion mutant also significantly decreased (*P* \< 0.0001, [Figure 5](#F5){ref-type="fig"}). We speculated that Lgt influences *S. aureus* BA formation by affecting the maturation of IsdE proteins. This hypothesis, however, requires further investigation.

*Staphylococcus aureus* produces numerous pathogenic toxins during infection ([@B63]). Unsurprisingly, the expression levels of several toxin genes of both strains increased in the BA model relative to those in the EC or BM models. These genes include the pore-forming toxin genes *hla* and *pvlF*, the protease gene *aur*, and the adenosine synthase gene *adsA* ([Figure 2B](#F2){ref-type="fig"}, 3B, 4). Thus, we selected these toxin genes for isogenic mutant analysis. As expected, the virulence of the Δ*hla* strain was impaired, and mice infected with the Δ*hla* strain showed reduced bacterial loads and shrunken BA volume. By contrast, *aur* does not seem to be required for BA formation ([Figure 5](#F5){ref-type="fig"}). The mechanism underlying Hla function may be attributed to its neurotoxic effects on brain cells *in vivo* and on isolated nerve terminals and cultured astrocytes *in vitro* ([@B16]). The *aur* gene encodes aureolysin, a metalloprotease that can modify the cell surface proteins of *S. aureus* through adhesin cleavage and contribute to immune escape from macrophages ([@B40]; [@B30]). Nevertheless, in a murine skin abscess model, *aur* inactivation only negligibly attenuates virulence ([@B50]). Our results suggest that Aur has a limited role in BA formation by *S. aureus*. The role of Panton--Valentine leukocidin (PVL, encoded by *pvlF* and *pvlS*) as a virulence determinant in mouse models has been questioned ([@B58]; [@B22]). The *adsA* gene encodes AdsA that likely participates in the synthesis of immune suppressors and has a global effect on the physiological properties of *S. aureus* ([@B55]). We were unable to obtain viable isogenic mutant Δ*pvlF* and Δ*adsA* strains given technical problems. In future work, we will determine the roles of PVL and AdsA in BA formation through *S. aureus* infection.

After identifying eight genes that encode immune evasion factors, we demonstrated that the *spa* gene, which encodes SpA, plays crucial roles in staphylococcal abscess formation. More than 90% of staphylococcus strains carry the *spa* gene ([@B57]). SpA anchors to the bacterial cell wall and is released during bacterial growth; it can protect staphylococci from opsonophagocytic killing by reducing the antibody-mediated binding of bacteria or promote B-cell proliferation and apoptosis by acting as a B-cell superantigen that crosslinks the Fab domain of V~H~3-type B-cell receptors ([@B52]; [@B11]). SpA variants exhibited attenuated abilities to form surface and renal abscesses ([@B14]). In this study, we observed that the *spa* deletion mutant and *spa/hla* double mutant showed drastically attenuated virulence in BA formation ([Figure 5](#F5){ref-type="fig"}). Given these results, SpA and Hla are promising targets for the treatment of *S. aureus* BA infections.

Brain abscesses treatment is highly complicated and requires combined medical and surgical approaches ([@B8]; [@B47]). The intensifying antibiotic resistance of bacteria involved in BA infections exacerbates the outcome of BA patients. Newly developed antivirulence therapeutics that neutralize bacterial toxins or block the pathways involved in virulence factor production are attractive options for the treatment of bacterial infections ([@B29]; [@B44]). Enzymes, such as CrtN for carotenoid pigment synthesis, and toxins, such as Hla, Hlb, and PSMα, are promising targets in novel therapeutic paradigms against *S. aureus* infections ([@B13]; [@B29]; [@B61]). Neutralizing mAbs have attracted increased attention as potential antivirulence compounds since the FDA approved the use of mAbs against anthrax in 2009 ([@B29]). Several studies have shown that anti-Hla mAbs confer a high degree of protection against lethal pneumonia with *S. aureus* origins and reduce abscess formation by *S. aureus* in a dermonecrosis model ([@B56]; [@B19]; [@B24]). Other researchers have proposed that bacterial infections could be treated effectively by a combination of antivirulence components that collectively target different types of virulence factors ([@B15]; [@B1]). In this study, we showed that treatment with Hla and SpA mAbs significantly decreased *S. aureus* loads in BA (*P* \< 0.05) and reduced BA volume (*P* \< 0.01) compared with treatment with PBS ([Figure 6](#F6){ref-type="fig"}). This result suggests that mAbs therapy is an effective strategy for the treatment of BA caused by *S. aureus* infection. The selectiveness of mAbs is higher than that of antibiotics, which often fail to distinguish pathogens from nonpathogenic strains and may cause microfloral disequilibrium ([@B20]). Despite this advantage, however, the poor penetration of the blood--brain barrier (BBB) by mAbs hinders their application in BA treatment ([@B18]). [@B41] used fluorescein isothiocyanate-labeled dextran (40 kDa) to demonstrate that *S. aureus* infection can enhance the permeability of the BBB by decreasing vascular endothelial cadherin, claudin-5, and zonula occludens-1 levels in a dose-dependent manner. Moreover, [@B4] reported that in the murine BA model, staphylococcal BA development results in the persistent opening of the BBB. This effect may favor the distribution of antibody drugs to the central nervous system. The *S. aureus* factors that participate in BBB opening warrant further investigation.

In conclusion, we applied *in vivo* virulence gene expression and isogenic mutant analyses to identify a set of five genes, namely, *isdA, isdC, lgt, hla*, and *spa*, that encode essential virulence factors involved in BA formation. Our results suggest that these five genes have prominent roles in the pathogenesis of staphylococcal BA. Our results also demonstrate that the genes of *S. aureus* are differentially expressed in different disease states and in response to the host environment. By applying Hla and SpA as therapeutic targets, we further demonstrated that mAbs therapy is an attractive option for the treatment of BA infections. Our results provide further insight on the management of BA, particularly BA caused by infection with *S. aureus*.
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